Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
MedChem Buzz
Kilomentor
On Pharma
A New Merck, Reviewed
Liberal Arts Chemistry
One in Ten Thousand
Electron Pusher
Periodic Tabloid
All Things Metathesis
C&E News Blog
Propter Doc
Chemiotics II
The Chemical Notebook
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
Chirality
BBSRC/Douglas Kell
ChemBark
Drug Discovery Opinion
Realizations in Biostatistics
Chemjobber
Pharmalot
WSJ Health Blog
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Useful Chemistry
Chiral Jones
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Totally Synthetic
Fragment Literature
The F- Blog
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Carbon-Based Curiosities
Experimental Error
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Chemical Forums
Depth-First
Symyx Blog
P212121
ChemCafe
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Speculist
Cosmic Variance
The Capsule
Zeroth Order Approximation
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« pHooey | Main | More Fun With Impact Factors »

August 30, 2005

Our Friend the Impact Factor

Email This Entry

Posted by Derek

I had an email asking if scientists in industry care about journal impact factors. It's an interesting question, but it needs to be answered in parts. Unless you deal with academic publishing, the phrase probably doesn't mean much. "Impact factors" are an attempt to quantify what everyone knows empirically: some journals are more prestigious than others. You know how we science types love to quantify stuff.

The whole business comes from the folks at ISI (now owned by Thomson.) They had been publishing the Citation Index for years, which was (and is) a way to find out who had referenced a given paper in the scientific literature after it was published. This can be useful if you want to see if anyone's followed up or commented on an interesting paper (or if you just want to see if anyone's cited your own work.)

And as ISI realized early on, it could also furnish some interesting rankings of "most-cited" papers in a given field. (Here's a recent set of lists from Chemical Abstracts, the big dog in the chemical information world, who got into the citation-counting business themselves.) You could figure out who the most cited authors are, too, although that ISI link won't rank-order them for you. (You have to pay for that data! Or you can look here.) There are lists of the most highly cited institutions, too, naturally.

About ten years ago, they introduced the Impact Factor to do the same thing for scientific journals. That's the number of citations generated by a journal (usually over a multiyear period) divided by the number of papers it published in that time: the average number of cites per paper, in other words.

The publishing community - initially rather worried and sceptical, if my memory serves - has gone completely crazy over the whole idea. Now journals advertise themselves by their impact factors. "Publish here! We're a good journal, really! We have proof!" If you'd like to know what a particular journal's rating is, they'll probably shout it out if it's any good at all. A failure to mention the number, down to three decimal places, is an act that speaks for itself.

Want the whole list? It can be rather hard to come by, unless you're a paying customer of ISI's, but here's a place to start. Those aren't the latest figures, but they'll do. You'll notice that at the top are a bunch of review journals, who publish comparatively few papers but get cited out the wazoo. Among the original-research journals in the top ranks are big kahunas like Cell, Nature, the New England Journal of Medicine, Science, and such. But I find a perverse fascination in browsing the low end of the scale. The Ethiopian Medical Journal? Fertiliser Research? Bovine Practice? Annals of Saudi Medicine? Surely some of these trench-dwellers ceased publication and vanished from sight during the rating period. The list of "0.000" impact factors is particularly alarming, although most of the journals listed are there by some sort of statistical artifact or (I presume) don't really exist. But if no one reads them, how do we know if they're real or not?

In the next installment, we'll look at some problems with the whole idea - there are some - and I'll tell you if we industrial types give a hoot about it or not. . .

Comments (6) + TrackBacks (0) | Category: The Scientific Literature


COMMENTS

1. jsinger on August 31, 2005 8:27 AM writes...

...or (I presume) don't really exist. But if no one reads them, how do we know if they're real or not?

I once found a paper mentioned in a reference list in a journal that I just could not obtain anywhere. Not in Medline, not through any academic library exchange, not through a commercial service.

I went over to Harvard Med School and was informed (with the humility characteristic of that institution): "Sir, if Countway doesn't have that journal, it doesn't exist."

Permalink to Comment

2. Derek Lowe on August 31, 2005 9:08 AM writes...

Or, as it was put in the context of Balliol College, Oxford (about Benjamin Jowett):

"First come I; my name is Jowett.
There's no knowledge but I know it.
I am the master of this college,
What I don't know isn't Knowledge."

Permalink to Comment

3. Rich Y on August 31, 2005 9:36 AM writes...

Looking through that list of 0.000s, I'm sure some of them are statistical artifacts.

Now, I know for a fact that the IEEE Journal of Selected Topics in Quantum Electronics is a reasonably well cited journal. It's not exactly Nature, but it is one of the more important journals in the subcommunity of people who study and build lasers. I'd expect it wouldn't even be near the bottom of the IEEE journals.

Permalink to Comment

4. Gerald Bothe on August 31, 2005 9:50 AM writes...

The 0.000 impact factors are indeed a methodological artifact. Only the journals listed in the Science Citation Index are used to calculate the factor. Thus, if the Paraguayan Journal of Entomology is never cited in Science etc., it has an impact factor of zero, not matter how often it is cited in Dipterologist's Digest (assuming that Dipterologist's Digest is not included in SCI). They hid this information deep down in the definition of the Impact Factor, see http://www.isinet.com/essays/journalcitationreports/7.html/ and look for the difference between citING and citED-only journals...at least that's how I interpret that section.

Gerald

Permalink to Comment

5. biohombre on August 31, 2005 12:10 PM writes...

It may be useful to also recall that it is in the best interests of academic researchers to slightly manipulate citation indices. To illustrate what I mean by that comment- consider what happened to myself, and others that have published "a first" in the same year as another lab. I was in a "low citation index" lab as a graduate student, the other author was in a "high citation" lab. If you trace the citations in the literature you will find that our publication is almost never cited. This of course is in the best interest of the other author, who will cite themself. It is also in the best interest of others citing this literature. Why? The other author has considerable influence in NIH study sections...

But having worked a number of years in industry, I also know that some good science that is critical in problem-solving (such as- what is REAL from that academic publication/patent) will never be published. (Heaven forbid, it may question the validity of that patent your company just licensed!)

Oops, maybe I should have held these comments until Derek's next installment?

Permalink to Comment

6. Brian Hawkins on August 31, 2005 4:46 PM writes...

Interesting...I never knew that IF was intended to represent the average number of citations per paper (though it makes perfect sense).

I might be anticipating your next post a bit, but it seems to me that since some papers get cited hundreds (even thousands) of times, and an impact factor of >10 puts you in the top 1%, the "typical" paper in what is considered a high-impact journal might not be cited all that much more than a paper in a journal with an impact factor of, say, 3.

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Academia and Industry, Suing Each Other
Let's Start Off the Meeting With An Ad, OK?
The Academic-Industrial Collaboration in Drug Discovery Panel: Today
Glass Structure, Atom by Atom
How the Andrulis Paper Got Published
AstraZeneca in Waltham
Fluorine NMR: Why Not?
AstraZeneca Layoffs and Closings